WO2001034172A3 - Procedes et compositions pour traiter un syndrome d'insatisfaction - Google Patents

Procedes et compositions pour traiter un syndrome d'insatisfaction Download PDF

Info

Publication number
WO2001034172A3
WO2001034172A3 PCT/US2000/030312 US0030312W WO0134172A3 WO 2001034172 A3 WO2001034172 A3 WO 2001034172A3 US 0030312 W US0030312 W US 0030312W WO 0134172 A3 WO0134172 A3 WO 0134172A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treating
methods
deficiency syndrome
reward deficiency
Prior art date
Application number
PCT/US2000/030312
Other languages
English (en)
Other versions
WO2001034172A2 (fr
Inventor
Gregory M Sullivan
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Priority to AU13598/01A priority Critical patent/AU1359801A/en
Publication of WO2001034172A2 publication Critical patent/WO2001034172A2/fr
Publication of WO2001034172A3 publication Critical patent/WO2001034172A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés et des compositions pour traiter le Syndrome d'insatisfaction (RDS) par une quantité thérapeutiquement efficace d'inhibiteur B mono-amine oxydase. L'invention concerne également des compositions utilisées pour traiter le RDS comportant de la sélégiline à très faible dose.
PCT/US2000/030312 1999-11-05 2000-11-03 Procedes et compositions pour traiter un syndrome d'insatisfaction WO2001034172A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13598/01A AU1359801A (en) 1999-11-05 2000-11-03 Methods and compositions for treating reward deficiency syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16370899P 1999-11-05 1999-11-05
US60/163,708 1999-11-05

Publications (2)

Publication Number Publication Date
WO2001034172A2 WO2001034172A2 (fr) 2001-05-17
WO2001034172A3 true WO2001034172A3 (fr) 2001-10-25

Family

ID=22591235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030312 WO2001034172A2 (fr) 1999-11-05 2000-11-03 Procedes et compositions pour traiter un syndrome d'insatisfaction

Country Status (2)

Country Link
AU (1) AU1359801A (fr)
WO (1) WO2001034172A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8595055B2 (en) 2001-03-27 2013-11-26 Points.Com Apparatus and method of facilitating the exchange of points between selected entities
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
KR100681585B1 (ko) 2002-04-26 2007-02-09 에프. 호프만-라 로슈 아게 아이소퀴놀린 유도체
DK1511718T3 (da) 2002-05-29 2009-06-22 Hoffmann La Roche N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
TWI286132B (en) 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
CN100418954C (zh) 2002-12-13 2008-09-17 弗·哈夫曼-拉罗切有限公司 3h-喹唑啉-4-酮衍生物
US7148362B2 (en) 2003-09-18 2006-12-12 Hoffmann-La Roche Inc. Process for the preparation of enantiopure pyrrolidin-2-one derivatives
CA2543287A1 (fr) 2003-10-23 2005-05-06 F.Hoffmann-La Roche Ag Derives de benzazepine utiles comme inhibiteurs de mao-b
EP1588704A1 (fr) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
ES2319213T3 (es) 2004-06-23 2009-05-05 F. Hoffmann-La Roche Ag Inhibidores de mao-b.
AU2005268894B2 (en) 2004-08-02 2010-12-16 F. Hoffmann-La Roche Ag Benzyloxy derivatives as MAOB inhibitors
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
JP4796620B2 (ja) 2005-03-15 2011-10-19 エフ．ホフマン−ラ ロシュ アーゲー エナンチオマー的に純粋な４−ピロリジノフェニルベンジルエーテル誘導体の製造方法
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN114903134A (zh) 2014-12-09 2022-08-16 以西结·戈兰 酒精饮料替代品
EP3705469A1 (fr) * 2014-12-09 2020-09-09 GOLAN, Ezekiel Régulateurs de comportement excessif

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812481A (en) * 1986-04-16 1989-03-14 Degussa Aktiengesellschaft Synergistic combination of amantadiene and selegiline
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
US5721258A (en) * 1993-08-17 1998-02-24 Asta Medica Aktiengesellschaft Primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812481A (en) * 1986-04-16 1989-03-14 Degussa Aktiengesellschaft Synergistic combination of amantadiene and selegiline
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
US5721258A (en) * 1993-08-17 1998-02-24 Asta Medica Aktiengesellschaft Primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases

Also Published As

Publication number Publication date
AU1359801A (en) 2001-06-06
WO2001034172A2 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2001034172A3 (fr) Procedes et compositions pour traiter un syndrome d'insatisfaction
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
YU5003A (sh) Nova farmaceutska smeša
EP1378240A3 (fr) Compositions pharmaceutiques à base d'arsenic pour le traitement du myelome multiple
ZA99913B (en) Alteration of amino acid compositions in seeds.
SE9803710L (sv) Användning av vissa substanser för behandling av nervrotsskador
HK1056878A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
WO2002089791A3 (fr) Traitement de l'acne
AP9901674A0 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
SI0814789T1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
NZ531404A (en) Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
WO2003047558A3 (fr) Traitement de troubles du systeme nerveux central a l'aide d'inhibiteurs de d-amino-oxydase et de d-aspartate oxydase
WO2002039994A3 (fr) Methodes de traitement et de prevention des calculs urinaires
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
AU2001268233A1 (en) Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
WO2001030334A3 (fr) Promedicaments a base d'acide 6-methoxy-2-naphthylacetique
WO2005041886A3 (fr) Procedes permettant de generer ou d'augmenter des revenus lies au commerce des inhibiteurs de la douleur
IL130500A0 (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
WO2001088530A3 (fr) Procede de selection d'inhibiteurs d'enzymes
WO2001000189A3 (fr) Combinaison d'inhibiteurs de mtp et principes actifs agissant sur le metabolisme et leur utilisation dans les medicaments
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
ATE290878T1 (de) Inhibierung von invasiver remodulierung
WO1998047494A3 (fr) Nouvelle utilisation d'inhibiteurs de metalloproteinase matricielle
ZA992400B (en) Process for hot-rolling stainless steel and surface treatment compositions used therein.
WO2002028398A1 (fr) Compositions destinees au traitement du diabete

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase